Balyasny Asset Management
INDV icon

Balyasny Asset Management’s Indivior Pharmaceuticals INDV Stock Holding History

Balyasny Asset Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$278K Buy
+9,121
New +$301K ﹤0.01% 2589
2025
Q2 		– Sell
-54,321
Closed -$518K – 3070
2025
Q1 		$518K Buy
54,321
+17,940
+49% +$189K ﹤0.01% 2258
2024
Q4 		$452K Buy
36,381
+21,379
+143% +$220K ﹤0.01% 2232
2024
Q3 		$146K Sell
15,002
-42,321
-74% -$496K ﹤0.01% 2609
2024
Q2 		$924K Sell
57,323
-120,179
-68% -$2.17M ﹤0.01% 1825
2024
Q1 		$3.8M Buy
+177,502
New +$3.33M 0.01% 1327

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Balyasny Asset Management's INDV Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Indivior Pharmaceuticals (INDV) in Q1 2026: 9,121 shares worth $278K. The stake represents ﹤0.01% of the portfolio and ranks #2589 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in INDV as recently as Q1 2025.

Balyasny Asset Management first reported a position in INDV in Q1 2024 and has held it in 6 quarters since. The position peaked at $3.8M in Q1 2024. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Balyasny Asset Management held 9,121 shares of Indivior Pharmaceuticals worth $278K as of Q1 2026.
  • Indivior Pharmaceuticals was a new Balyasny Asset Management position in Q1 2026.
  • Indivior Pharmaceuticals made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2589 holding.
  • Balyasny Asset Management first reported a position in Indivior Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
  • Balyasny Asset Management's Indivior Pharmaceuticals position peaked at $3.8M in Q1 2024.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.